Figure 4 | Scientific Reports

Figure 4

From: Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment

Figure 4

AGF94 efficacy trial in the IP BR-Luc model. Overall survival (A) and tumor burden (C) are shown for IP BR-Luc tumors in FVB mice following treatment with AGF94 (32 mg/kg × 4 doses). (A) A Kaplan–Meier survival analysis was performed on 4 mice treated with AGF94 (32 mg/kg × 4 doses). For control mice, a median of 22 days was measured compared to a median of 33 days for the AGF94-treated mice. Statistical analysis was performed using the log-rank test. (B) The treatment scheme is shown. (C) Luminescent images are shown for a separate cohort (3 mice) over 3 min for control and AGF94-treated mice treated with 4 doses at 32 mg/kg and overlayed on top of an X-ray image.

Back to article page